IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, announces today the nomination of Suzette Kox as Secretary General of the association. Her main role is to coordinate the IGBA activities as IGBA continues to expand its outreach relevant to its mission, priorities and operations.
IGBA proposes a new international biosimilars framework allowing bridging studies to be waived in specific circumstances based on core scientific and regulatory principles established for current products.
IGBA Position on Identification of Biological, including Biosimilar Medicines 2018 Update of Facts & Figures.
- IGBA submission to HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs [RIN 0991-ZA49]
- Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest
- IGBA Joins ICH Management Committee and Welcomes the Positive Vote of the General Assembly
- IGBA launches a biosimilar medicines information campaign